 CAMBRIDGE, Mass., Jan. 05, 2021 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. NASDAQ:MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today provided corporate and pipeline updates and announced its goals and anticipated milestones for 2021. 